B-Cell Lymphoma — Malignancy of Immune B Lymphocytes

B-cell lymphoma develops when genetic mutations disrupt the normal maturation, proliferation, and programmed death of B lymphocytes. Under normal conditions, these cells defend the body by synthesising protective antibodies. When transformed, malignant B cells bypass immunological checkpoints, proliferating unchecked within lymph nodes, bone marrow, and extranodal tissues such as the gastrointestinal tract, liver, or central nervous system.

Pathologically, B-cell lymphomas account for roughly 85 percent of all non-Hodgkin lymphomas and are broadly stratified by clinical behaviour. Indolent subtypes, such as follicular lymphoma, grow slowly and may persist for years with minimal symptoms. In contrast, aggressive forms, such as diffuse large B-cell lymphoma or Burkitt lymphoma, proliferate rapidly, demanding prompt, intensive systemic intervention.

Knowing you have a B-cell lymphoma—and specifically which subtype—is vital because therapeutic strategies vary dramatically. An indolent lymphoma might only need active surveillance, sparing you from immediate drug toxicity, whereas an aggressive subtype requires prompt combination chemoimmunotherapy with curative intent. Knowing the specific cellular markers on your lymphoma cells also guides targeted therapy choices, giving your healthcare team precise options designed to destroy malignant cells while preserving healthy tissues as much as possible.

Diagnosis requires an excisional or core biopsy of an affected lymph node for histopathology. Flow cytometry and immunohistochemistry assess characteristic surface proteins like CD19, CD20, and CD79a. Molecular tests and fluorescence in situ hybridisation detect crucial gene rearrangements, such as BCL2, BCL6, and MYC. Staging involves PET-CT imaging and occasional bone marrow assessment.

This term represents a major category of non-Hodgkin lymphoma. Notable aggressive forms include diffuse large B-cell lymphoma, mantle cell lymphoma, and Burkitt lymphoma. Prominent indolent forms include follicular lymphoma, marginal zone lymphoma, and chronic lymphocytic leukaemia or small lymphocytic lymphoma. Primary central nervous system lymphoma is another specialised B-cell malignancy.

Treatments frequently incorporate monoclonal antibodies targeting B-cell surface antigens, most notably anti-CD20 drugs like rituximab, combined with chemotherapy regimens such as CHOP. Advanced or refractory diseases may be treated with targeted small molecules like BTK inhibitors, bispecific antibodies, or CAR T-cell therapies. Radiation therapy is often utilised for localised disease or symptom relief.